我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

美托洛尔部分逆转心力衰竭恶病质作用的观察(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2006年第1期
页码:
79-80，86
栏目:
临床研究
出版日期:
2006-01-01

文章信息/Info

Title:
Partial reversal of cachexia by Metoprolol therapy in patients with chronic heart failure
作者:
田颖;  李振魁;  王江;  于林君; 周裔忠;  祝善俊
第三军医大学新桥医院心内科，重庆 400037
Author(s):
TIAN Ying;  LI Zhen-kui;  WANG Jiang;  YU Lin-jun;  ZHOU Yi-zhong;  ZHU Shan-jun
Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
关键词:
心力衰竭; 恶病质; 体质量; 细胞因子; 美托洛尔
Keywords:
heart failure;  cachexia;  body weight;  cytokine;  Metoprolol
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的 探讨美托洛尔对心力衰竭恶病质患者体质量及血浆细胞因子水平变化的影响。方法 选择心力衰竭患者分为恶病质组和非恶病质组，给予美托洛尔治疗。检测患者治疗前后体质量、血浆肿瘤坏死因子α（TNF-α）、白介素-1β（IL-1β）和白介素-6（IL-6）的变化及不良事件发生率。结果 治疗后两组患者血浆TNF-α、IL-1β和IL6较治疗前显著降低，恶病质组改变更为显著，且恶病质组体质量显著增加；治疗前后恶病质组体质量均低于非恶病质组，血浆TNF-α、IL-1β水平则均高于非恶病质组，IL-6无显著差异。结论 美托洛尔可以增加心力衰竭恶病质患者体质量，同时能降低血浆细胞因子浓度，有利于心力衰竭恶病质状态的逆转。
Abstract:
AIM To explore the effects of Metoprolol(β-adrenergic receptor blockade) therapy on body weight and plasma cytokine level in chronic heart failure(CHF) patients with cachectic. METHODS The patients with CHF were divide into cachectic group and noncachectic group. Body weight， plasma tumor necrosis factor alpha(TNF-α), interleukin-1β(IL-1β),interleukin-6(IL-6) levels and incidence of adverse events were measured before and after Metoprolol therapy. RRSULTS Six months after Metoprolol therapy, subjects demonstrated significantly greater decrease in plasma TNF-α,IL-1β and IL-6 in both groups especially in cachectic group and greater weight gain in cachectic group. Before and after therapy, subjects with cachectic demonstrated significantly lower body weight, much higher plasma TNF-α、IL-1β and no difference in IL-6 when compared with noncachectic. CONCLUSION Metoprolol therapy is associated with body weight gain and decrease of plasma cytokine level,which is conducine to reversal of cachexia.

参考文献/References

［1］ Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure［J］. Lancet,1997, 349:1050-1053.

［2］ Prabhu SD, Chandrasekar B, Murray DR, et al. βAdrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling［J］. Circulation, 2000, 101:2103-2109.

［3］ Deten A, Volz HC, Holzl A, et al. Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats［J］. Mol Cell Biochem, 2003, 251:127-137.

［4］ 祝善俊，徐成斌. 心力衰竭基础与临床［M］.北京:人民军医出版社，2001. 183.

［5］ Anker SD, Sharma R. The syndrome of cardiac cachexia［J］. Int J Cardiol, 2002, 85:51-66.

［6］ Brink M, Anwar A, Delafontaine P. Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia［J］. Int J Cardiol, 2002, 85:111-121.

［7］ Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: An example of a systemic chronic inflammatory disease resulting in cachexia［J］. Int J Cardiol, 2002, 85:33-49.

［8］ 王晓明，李源，李慧芳, 等. 心力衰竭患者血清中TNFα、IL1β及IL6的变化［J］. 心脏杂志, 2002, 14:318-322.

［9］ Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Betaadrenergic receptor blockers and weight gain: a systematic analysis［J］. Hypertension, 2001, 37:250-254.

［10］Hryniewicz K, Androne AS, Hudaihed A, et al. Partial reversal of cachexia by betaadrenergic receptor blocker therapy in patients with chronic heart failure［J］. J Card Fail, 2003, 9:464-468.

备注/Memo

备注/Memo:
收稿日期：2004-10-08.通讯作者：祝善俊，主任医师，博导，主要从事心力衰竭基础与临床的研究 Tel:(023)68755071 作者简介：田颖，医师，博士生 Tel：(023)66350239 Email：doctorty2000@163.com
更新日期/Last Update: